Prior to the arrival of GLP1 receptor agonists, weight loss medications had modest impacts on weight loss and were frequently poorly tolerated
Both Qsymia and GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved for chronic weight management
The 5-day spacing between injections reflects the pharmacodynamics of how MOTS-c signals at the mitochondrial level
Do not use if you are pregnant, planning to become pregnant, or breastfeeding unless your healthcare provider decides it is clearly needed, because safety data are limited
Weight loss of 2-5 kg is typical over 6-12 months
Though not identical, Ozempic interacts with the same receptors, providing similar benefits such as improved blood sugar control, slowed digestion, and reduced appetite